Zimmer Biomet Q1 sales jump 9.3% on Paragon 28 deal, $30M tariff refund, and FX tailwinds

Filed May 1, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 5, 2025 · ~1 min read

Key Changes

• high

  Q1 2026 net sales grew 9.3% vs. 1.1% in Q1 2025, driven by Paragon 28 acquisition (3.9 pts), favorable FX (2.5 pts), and opportunistic customer purchases. Net earnings rose 31% to $238M, boosted by a one-time $30M tariff refund adjustment.

  MD&A: Q1 Results verify on EDGAR →
• high

  Full-year 2026 sales growth outlook lowered to 2.5%-4.5% from 2025's 5.7%-8.2% target, citing headwinds from U.S. go-to-market strategy changes, international execution challenges, and price declines. Operating profit expected to grow despite revenue deceleration.

  MD&A: 2026 Outlook verify on EDGAR →
• high

  2025 Restructuring Plan expanded 82%: total charges now $155M (from $85M) with expected annual savings of $175M (from $95M). $143M of charges already incurred through Q1 2026, indicating plan is substantially complete.

  MD&A: Restructuring verify on EDGAR →